Cooper S A
School of Dental Medicine, University of Pennsylvania, Philadelphia 19104.
J Clin Pharmacol. 1988 Dec;28(s1):S40-6. doi: 10.1002/j.1552-4604.1988.tb05976.x.
Ketoprofen is a new peripherally acting analgesic and the most recently introduced nonsteroidal anti-inflammatory drug in the United States with indication for management of nonarthritic pain. Three 6-hour double-blind, single-dose, placebo-controlled studies in which patients who had undergone dental impaction surgery took ketoprofen or a comparator drug are reviewed. In the first study, ketoprofen 25, 50, and 100 mg was compared with aspirin 650 mg and placebo in 153 patients. In comparison with aspirin, significant (P less than 0.001) differences favoring ketoprofen at each dose level were found for all measures of analgesic efficacy. For the combined ketoprofen groups, 60% of the patients rated treatment as very good or excellent, compared with 16% in the aspirin group. The second study compared ketoprofen 25, 50, and 100 mg with codeine 90 mg and placebo in 129 patients. Ketoprofen appeared to have a more rapid onset, higher peak effect, and longer duration of pain relief than codeine. At least 70% of patients in each of the ketoprofen groups rated the test medication as very good or excellent, compared with only 7% of the patients in the codeine group. The third study compared ketoprofen 25 and 100 mg with ibuprofen 400 mg and placebo in 161 patients. Ketoprofen 100 mg had a faster onset of effect, the highest peak effect, and the longest duration of action over the 6-hour evaluation. Ketoprofen treatment was not associated with any unusual or serious side effects in any of the three studies.(ABSTRACT TRUNCATED AT 250 WORDS)
酮洛芬是一种新型外周作用性镇痛药,也是美国最近引入的用于治疗非关节炎性疼痛的非甾体抗炎药。本文回顾了三项为期6小时的双盲、单剂量、安慰剂对照研究,这些研究中接受拔牙手术的患者服用了酮洛芬或对照药物。在第一项研究中,153名患者中,将25毫克、50毫克和100毫克的酮洛芬与650毫克阿司匹林及安慰剂进行了比较。与阿司匹林相比,在每个剂量水平上,酮洛芬在所有镇痛效果指标上均有显著(P<0.001)差异,更具优势。对于合并的酮洛芬组,60%的患者将治疗评为非常好或优秀,而阿司匹林组为16%。第二项研究在129名患者中,将25毫克、50毫克和100毫克的酮洛芬与90毫克可待因及安慰剂进行了比较。酮洛芬似乎起效更快、峰值效应更高、止痛持续时间更长。酮洛芬各治疗组中至少70%的患者将受试药物评为非常好或优秀,而可待因组仅7%。第三项研究在161名患者中,将25毫克和100毫克的酮洛芬与400毫克布洛芬及安慰剂进行了比较。在6小时的评估中,100毫克酮洛芬起效更快、峰值效应最高、作用持续时间最长。在三项研究中的任何一项中,酮洛芬治疗均未出现任何异常或严重的副作用。(摘要截选至250字)